Shares of Organogenesis Holdings Inc (ORGO) tumbled 7.08% in pre-market trading on Friday, as investors reacted to the company's disappointing second-quarter earnings report released after market close on Thursday. The biotechnology company, which specializes in regenerative medicine, posted results that fell short of analyst expectations, sparking a sell-off in early trading.

For the quarter ended June 30, Organogenesis reported a quarterly adjusted loss of 10 cents per share, significantly wider than the 6 cents loss per share analysts had predicted. This result also marked a substantial decline from the same quarter last year when the company reported earnings of 4 cents per share. Revenue for the quarter fell 22.4% to $101.01 million, missing the analyst consensus of $103.40 million. The company's bottom line showed a quarterly loss of $12.2 million, highlighting the challenges faced during the period.

Despite the pre-market plunge, it's worth noting that Organogenesis shares had performed well leading up to this earnings report. The stock had risen by 23.0% over the quarter and gained 40.6% year-to-date. However, this earnings miss may dampen investor enthusiasm in the near term. Wall Street maintains a generally positive outlook on the stock, with a consensus "buy" rating and a median 12-month price target of $7.00, which represents a 35.4% upside from its last closing price of $4.52. As the market digests this earnings report, investors will be closely watching how Organogenesis plans to address its challenges and return to profitability in the coming quarters.